learn Dutasteride
Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata
Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
research Fatal Toxic Epidermal Necrolysis Associated With Minoxidil
Minoxidil can cause deadly skin reaction; monitor patients closely.
research Phytochemicals and Novel Delivery Systems in Alopecia Management: An Integrative Review
Combining herbal medicines with modern delivery systems may improve alopecia treatment.
research Exploring the Efficacy of Baricitinib in Treating Alopecia Areata After Failed Janus Kinase Inhibitor Therapy
Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
Community Join
5 / 172 resultscommunity Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
community Prepare to be disappointed by PP405
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
community People are hyped about PP405 but what about Veradermics phase 2!
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.